Please see the article here for a Q+A interview with Dunad CEO Pearl Huang in Nature Reviews Drug Discovery.

NT-0796 successfully completes Phase 1 study, demonstrating blood-brain barrier penetration and reduced inflammatory biomarkers supporting advancement in neuroinflammatory   and peripheral inflammatory diseases Second clinical candidate

MIAMI – RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced that it has raised an additional $10.5 million,

Edinburgh and Cambridge, UK, 12 September 2022 – Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr

Pegcetacoplan treatment effect accelerated between months 18-24, demonstrating a robust reduction of GA lesion growth compared to sham (all p-values are nominal) DERBY: 36% monthly,

Dr. Huang brings more than 30 years of biopharma experience, most recently as Chief Executive Officer and President of Flagship Pioneering start-up Cygnal Therapeutics Dunad

Andy Billinton PhD appointed as Chief Scientific Officer Expansion into larger facilities at the Babraham Research Campus  Cambridge, 23rd June 2022: Transine Therapeutics today announced

Dr Alison Strutt joins Kynos senior management team as CFO Brings extensive strategic, transactional, and operational experience in biotech and large pharma to the Kynos